Combining Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen–Positive Patients With Chronic Hepatitis B
Authors:
- 25 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 222 (4) , 611-618
Abstract
Background: Safe nucleos(t)ide analogue discontinuation in chronic hepatitis B (CHB) is an unmet need. We aimed to investigate whether combining hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) could perform satisfactorily in predicting off-treatment outcomes. Methods: The evaluation cohort included 127 hepatitis B e antigen (HBeAg)–positive patients from a multicenter prospective trial who stopped telbivudine-based therapy after achieving HBeAg seroconversion and HBV DNA < 50 IU/mL for > 48 weeks. As validation, 59 patients treated with entecavir or tenofovir before discontinuation were analyzed. Results: At the end of treatment (EOT), HBV RNA and HBcrAg were significant independent predictors of the clinical relapse risk. In the evaluation cohort, no clinical relapse occurred among patients with negative HBV RNA and HBcrAg < 4 log10 U/mL at EOT (low-risk group), whereas 46.8% patients with positive HBV RNA and HBcrAg ≥ 4 log10 U/mL (high-risk group) experienced clinical relapse during 4-year posttreatment follow-up (P < .001); the corresponding incidences in the validation cohort were 0% and 69.4% (P < .001), respectively. More patients in the low-risk group achieved HBsAg loss than the other patients after treatment cessation (16.1% vs 1.3%, P = .002). Conclusions: Combining HBV RNA and HBcrAg performed satisfactorily in predicting clinical relapse and HBsAg loss after treatment cessation in HBeAg-positive patients with CHB. The combination of hepatitis B virus RNA and hepatitis B core–related antigen performed satisfactorily in predicting clinical relapse and hepatitis B surface antigen loss after stopping nucleos(t)ide analogue treatment among noncirrhotic hepatitis B e antigen–positive patients with chronic hepatitis B and could be used to guide safe discontinuation.Keywords
Funding Information
- National Natural Science Foundation of China (81700530, 81772187, 81971949)
- National Science and Technology Major Project of China (2017ZX10202202, 2018ZX10301202, 2017ZX10302201)
- Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131)
This publication has 16 references indexed in Scilit:
- Serum HBV pgRNA as a clinical marker for cccDNA activityJournal of Hepatology, 2017
- Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and reboundJournal of Hepatology, 2016
- Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patientsJournal of Gastroenterology, 2015
- JSH Guidelines for the Management of Hepatitis B Virus InfectionHepatology Research, 2014
- The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled studyHepatology, 2013
- Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patientsJournal of Gastroenterology, 2013
- Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosisHepatology, 2013
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up studyThe Lancet, 2013
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 updateHepatology International, 2012
- Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis BHepatology, 2010